A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 24 Jul 2026
At a glance
- Drugs BBT 002 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Proof of concept
- Sponsors Bambusa Therapeutics
Most Recent Events
- 15 Jun 2026 According to an Bambusa Therapeutics media release, Topline data from ongoing proof-of-concept trial evaluating BBT002 in patients with COPD anticipated by year-end 2026.
- 24 Dec 2025 New trial record